secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001437749-26-015586
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart reports Q1 net income $5.2M; COVID-19 sentinel data expected Q2 2026
---------------------------------------------------------------------------

- Q1 2026 net income $5.2M ($0.02/sh) vs net loss ($15.6M) in Q1 2025.
- Revenue $39.2M (+87% YoY) mainly from BARDA contract and Dynavax license.
- Cash $61.0M provides runway into Q2 2027; Lincoln Park equity facility up to $25M.
- Topline sentinel data from Phase 2b COVID-19 trial (400 participants) anticipated in Q2 2026.
- Appointed Dr. James B. Breitmeyer to board; relocated HQ to reduce overhead.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774926015586/0001437749-26-015586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774926015586/vxrt20260507_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-015586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer